Utang jangka dawa: karyopharm.com (KPTI)

This chart shows the market price of Karyopharm Therapeutics (KPTI) on the GURU.Markets platform at 0.00, while the business relies on ESG principles and strict bioethics in drug development. The company utilizes automated synthesis systems in production, although final patient oversight remains with physicians. However, intensifying competition and difficulties in servicing loans are exerting significant pressure on the company's financial stability.

This indicator aggregates total liabilities with maturities exceeding one year, allowing for an assessment of the issuer's strategic debt load and financial stability. The current volume of long-term debt for Karyopharm Therapeutics (KPTI) stands at 0.00, which, combined with the protection of developments in the US and EU, minimizes geopolitical risks and confirms the ability of Karyopharm Therapeutics (KPTI) to effectively finance innovative onco-hematological projects.